Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 220.00 | 1.96% | 11,416.00 | 11,412.00 | 11,414.00 | 11,442.00 | 11,226.00 | 11,226.00 | 1,382,390 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5370 | 25.16 | 173.6B |
From Mar 2020 to Mar 2025
By Denise Roland
AstraZeneca PLC said profit fell in the first quarter of the year as it battles declining sales of its blockbuster cholesterol pill.
Cambridge, England-based AstraZeneca said net profit fell 17% to $537 million in the three months to March 31, from $646 million a year earlier. Core operating profit, a measure that strips out one-time gains and impairments, slipped 2% to $1.67 billion, while revenue fell 12% to $5.41 billion. Analysts expected core operating profit of $1.4 billion and revenue of $5.4 billion.
Excluding the effect of the strong dollar, core operating profit increased 5% on a fall in research and development and marketing spending which offset a 10% decline in revenue.
AstraZeneca is working on a string of new drugs to help return the company to growth as the loss of patent protection erodes sales for its old blockbusters, such as cholesterol-lowering pill Crestor.
-Write to Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
April 27, 2017 02:44 ET (06:44 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
